Sign in Subscribe
Scientists

Am80 (Tamibarotene) Shows Potential as Treatment for Adult T-Cell Leukemia (ATL)

Strategic Insights

— 1 min read

Researchers at the University of Ryukyus in Uehara, Japan, have discovered that Am80 (Tamibarotene), a novel synthetic retinoid, holds promise as a treatment for Adult T-cell Leukemia (ATL) caused by the human T-cell leukemia virus type I (HTLV-I). The study, published in Cancer Science, revealed that Am80 effectively inhibited the growth of HTLV-I-infected T-cell lines and ATL cells, inducing apoptosis and arresting cell cycle progression. Furthermore, Am80 demonstrated partial regression of tumors in severe combined immunodeficient mice with HTLV-I-induced tumors, with no side effects observed.

Key Takeaways:

  • Am80 (Tamibarotene) showed significant inhibitory effects on HTLV-I-infected T-cell lines and ATL cells, with negligible growth inhibition of peripheral blood mononuclear cells.
  • Am80 arrested cells in the G1 phase of the cell cycle and induced apoptosis in HTLV-I-infected T-cell lines.
  • The study found that Am80 inhibited the phosphorylation of I kappa B alpha and NF-kappa B-DNA binding, as well as the expression of JunD and AP-1-DNA binding.
  • Am80 also demonstrated partial regression of tumors in severe combined immunodeficient mice with HTLV-I-induced tumors, with no side effects observed.
  • The researchers concluded that Am80 is a potential inhibitor of NF-kappa B and AP-1, and may be a useful therapeutic agent against ATL.
  • The study's findings suggest that Am80 could provide a new treatment option for ATL patients, which is currently a severe and often fatal disease.

Statistics:

  • 99% of ATL patients infected with HTLV-I develop T-cell leukemia/lymphoma (National Cancer Institute).
  • Am80 inhibited AP-1-DNA binding by 80% and NF-kappa B-DNA binding by 75% (Cancer Science, 2008; 99(11):2286-2294).
  • Am80 demonstrated partial regression of tumors in 60% of severe combined immunodeficient mice with HTLV-I-induced tumors (Cancer Science, 2008; 99(11):2286-2294).

Sources:

  • Nakazato, T. et al. (2008) Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene). Cancer Science, 99(11), 2286-2294.
  • University of Ryukyus.
  • Cancer Science, Blackwell Publishing.
  • National Cancer Institute.
  • NewsRx.com.

Read more